SEP 10, 2026 · PHASE 1/2 TRIAL
A Three-part First-in-human Trial to Assess Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of GUB-UCN2 in Healthy Lean and Obese Participants and Participants With T2D
ClinicalTrials.gov
This is a first-in-human Phase 1/2 trial registration with no results reported; the record describes planned enrollment and safety endpoints only.
Reported
Planned enrollment188
Primary outcome measureNumber of Treatment Emergent Adverse Events…
Treatment period duration (select…up to 16 weeks